Finance

Lists
Why is AKUMS down 2,51%?
Dive Deeper
AKUMS:NSE
Akums Drugs and Pharmaceuticals Ltd
731,00 INR
-2,51%
(-18,80) 1D
16-окт., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AKUMS...
Open
749,80 INR
High
752,80 INR
Low
728,70 INR
Mkt. cap
111,92 млд
Avg. vol.
272,03 миң
Volume
150,74 миң
Dividend
0,14%
Quarterly dividend
0,25 INR
Ex-dividend date
2026-ж., 3-июл.
P/E ratio
38,38
52-wk high
838,80 INR
52-wk low
409,30 INR
EPS
19,05 INR
No. of employees
7 миң
Open
749,80 INR
High
752,80 INR
Low
728,70 INR
Mkt. cap
111,92 млд
Avg. vol.
272,03 миң
Volume
150,74 миң
Dividend
0,14%
Quarterly dividend
0,25 INR
Ex-dividend date
2026-ж., 3-июл.
P/E ratio
38,38
52-wk high
838,80 INR
52-wk low
409,30 INR
EPS
19,05 INR
No. of employees
7 миң
News stories
From web sources and news partners
Profile
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical Contract Development and Manufacturing Organization that serves both domestic and multinational pharmaceutical companies. The company was established in 2004 and became publicly listed on 6 August 2024. Wikipedia
About Akums Drugs and Pharmaceuticals Ltd
CEO-
Employees7,34 миң
Founded2004
Headquarters-
SectorHealth care
Websiteakums.in
Last report
2026-ж., 10-авг.
Fiscal period
Q1 2027
6,53 INR / 6,10 INR
+7,05%beat
Revenue / Est. (INR)
11,67 млд / 11,65 млд
+0,14%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
10,18 млд
11,60 млд
11,60 млд
11,67 млд
Cost of goods sold
5,93 млд
6,79 млд
7,37 млд
6,45 млд
Cost of revenue
5,93 млд
6,79 млд
7,37 млд
6,45 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 млд
1,89 млд
2,37 млд
2,01 млд
Operating expense
3,68 млд
3,74 млд
3,09 млд
3,88 млд
Total operating expenses
9,61 млд
10,52 млд
10,46 млд
10,33 млд
Operating income
566,12 млн
1,07 млд
1,14 млд
1,34 млд
Other non operating income
323,65 млн
343,28 млн
-942,12 млн
303,80 млн
EBT including unusual items
656,73 млн
995,66 млн
1,21 млд
1,39 млд
EBT excluding unusual items
656,73 млн
1,18 млд
1,19 млд
1,39 млд
Income tax expense
229,77 млн
318,92 млн
398,74 млн
382,59 млн
Effective tax rate
34,99%
32,03%
32,89%
27,48%
Other operating expenses
1,41 млд
1,45 млд
319,86 млн
1,45 млд
Net income
407,83 млн
663,17 млн
846,13 млн
1,00 млд
Net profit margin
4,01%
5,72%
7,29%
8,57%
Earnings per share
2,66
5,14
-
6,53
Interest and investment income
-
-
1,10 млд
-
Interest expense
-233,04 млн
-237,42 млн
-184,41 млн
-247,56 млн
Net interest expenses
-233,04 млн
-237,42 млн
912,36 млн
-247,56 млн
Depreciation and amortization charges
378,64 млн
396,49 млн
401,18 млн
410,65 млн
EBITDA
940,04 млн
1,42 млд
1,49 млд
1,69 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору